These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 31150077)

  • 1. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
    Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
    JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
    Yeung K; Dusetzina SB; Basu A
    JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
    Rome BN; Feldman WB; Desai RJ; Kesselheim AS
    JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
    Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
    JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
    Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
    JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018.
    Lin SY; Baumann K; Zhou C; Zhou W; Cuellar AE; Xue H
    JAMA Netw Open; 2021 Nov; 4(11):e2135371. PubMed ID: 34807258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Retail Prices of Prescription Dermatologic Drugs From 2009 to 2015.
    Rosenberg ME; Rosenberg SP
    JAMA Dermatol; 2016 Feb; 152(2):158-63. PubMed ID: 26606197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.
    Desai A; Scheckel C; Jensen CJ; Orme J; Williams C; Shah N; Leventakos K; Adjei AA
    JAMA Netw Open; 2022 Jan; 5(1):e2144923. PubMed ID: 35076701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
    Gross DJ; Schondelmeyer SW; Raetzman SO
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
    Hayford TB
    JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of brand drug discount cards on private insurer, government and patient expenditures.
    Law MR; Chan FKI; Harrison M; Worthington HC
    CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic script share and the price of brand-name drugs: the role of consumer choice.
    Rizzo JA; Zeckhauser R
    Int J Health Care Finance Econ; 2009 Sep; 9(3):291-316. PubMed ID: 19130220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
    Cheng N; Banerjee T; Qian J; Hansen RA
    J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of Market Exclusivity for Prescription Drugs in the United States.
    Kesselheim AS; Sinha MS; Avorn J
    JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
    Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
    JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.